
Mesoblast Ltd
MESOHealthcare|Biotechnology|Australia
$15.46
+0.60 (+4.04%)
Tangible Book
$0.07
Analyst Estimates
annual
{
"date": [
"202606",
"202706",
"202806",
"202906",
"203006"
],
"revenue_estimate": [
127.99,
202.76,
296.38,
619.25,
886.44
],
"ebit_estimate": [
-38.69,
19.37,
87.71,
353.72,
571.16
],
"ebitda_estimate": [
null,
null,
null,
null,
null
],
"net_income_estimate": [
-56.41,
8.87,
77.71,
329.72,
515.75
],
"per_share_eps_estimate": [
-0.44,
0.06,
0.51,
2.12,
3.29
],
"eps_nri_estimate": [
-0.44,
0.06,
0.51,
2.12,
3.29
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-55.78,
8.87,
84.71,
350.72,
568.16
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
85.9,
87.8,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
257.58,
30.3,
7.31,
4.7
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "128.80",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 128.8,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 9.06,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 6.33,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706"
],
"revenue_estimate": [
36.91,
47.28,
49.34,
51.56,
57.4
],
"ebit_estimate": [
0.37,
10.19,
10.64,
11.22,
12.27
],
"ebitda_estimate": [
null,
null,
null,
null,
null
],
"net_income_estimate": [
0.37,
10.19,
10.64,
11.22,
12.27
],
"per_share_eps_estimate": [
null,
0.08,
0.08,
0.09,
0.07
],
"eps_nri_estimate": [
-0.11,
0.08,
0.08,
0.09,
0.07
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
0.37,
10.19,
10.64,
11.22,
12.27
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
null,
48.3,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "128.80",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 128.8,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 9.06,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 6.33,
"future_operating_cash_flow_per_share_estimate_growth": null
}